Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Assets: 2016-2024

Historic Assets for Collegium Pharmaceutical (COLL) over the last 9 years, with Dec 2024 value amounting to $1.7 billion.

  • Collegium Pharmaceutical's Assets fell 1.70% to $1.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 billion, marking a year-over-year decrease of 1.70%. This contributed to the annual value of $1.7 billion for FY2024, which is 45.51% up from last year.
  • As of FY2024, Collegium Pharmaceutical's Assets stood at $1.7 billion, which was up 45.51% from $1.1 billion recorded in FY2023.
  • In the past 5 years, Collegium Pharmaceutical's Assets ranged from a high of $1.7 billion in FY2024 and a low of $643.8 million during FY2020.
  • In the last 3 years, Collegium Pharmaceutical's Assets had a median value of $1.2 billion in 2022 and averaged $1.3 billion.
  • Its Assets has fluctuated over the past 5 years, first skyrocketed by 110.20% in 2020, then decreased by 2.63% in 2023.
  • Over the past 5 years, Collegium Pharmaceutical's Assets (Yearly) stood at $643.8 million in 2020, then increased by 7.49% to $692.1 million in 2021, then surged by 69.65% to $1.2 billion in 2022, then decreased by 2.63% to $1.1 billion in 2023, then skyrocketed by 45.51% to $1.7 billion in 2024.